Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus
- PMID: 11558867
- DOI: 10.1016/s0149-2918(01)80110-7
Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus
Abstract
Background: Drug use patterns among patients with type 2 diabetes mellitus have been studied in the general population but not specifically in the Medicaid population.
Objective: The purpose of this study was to examine antihyperglycemic drug use patterns among Medicaid recipients with type 2 diabetes and assess patients' persistence and compliance with different antihyperglycemic drug regimens.
Methods: Pharmaceutical claims data from Medi-Cal for January 1996 through September 1998 were analyzed to investigate antihyperglycemic drug use patterns over a 1-year and 2-year period. Prescription refill data were examined to assess patient compliance and persistence.
Results: Of the 37,431 patients in the 1-year follow-up cohort, 79.6% started antihyperglycemic treatment with monotherapy (ie, drug therapy with a single class of antihyperglycemic medication), 14.5% with insulin alone, 3.9% with polytherapy (ie, drug therapy with > or = 2 classes of medication other than insulin), and 2.1% with insulin plus another therapy. Of the patients receiving monotherapy, 85.3% were taking a sulfonylurea, 14.0% were taking metformin, and 0.7% were taking another agent. In the 1-year follow-up, 55.5% of patients taking metformin alone, 67.2% of those taking sulfonylurea alone, and 83.9% of those taking metformin plus sulfonylurea (M + S) did not undergo any modification of their regimen (except discontinuation of therapy). Among these patients, those taking metformin or sulfonylurea alone had approximately 65% more days of continuous (or persistent) treatment (129 and 128 days, respectively) per patient per year than did patients taking polytherapy (78 days). In addition, sulfonylurea or metformin monotherapy was associated with a 36% higher compliance rate than M + S polytherapy (177 days vs 130 days).
Conclusion: Simple 1-drug antihyperglycemic regimens were associated with better compliance and persistence (as measured by prescription refill data) than more complex multiple-drug regimens among patients with type 2 diabetes in the Medi-Cal population.
Similar articles
-
Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients.J Int Med Res. 2002 Jan-Feb;30(1):71-9. doi: 10.1177/147323000203000111. J Int Med Res. 2002. PMID: 11921502
-
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.Curr Med Res Opin. 2010 Jul;26(7):1697-703. doi: 10.1185/03007995.2010.489029. Curr Med Res Opin. 2010. PMID: 20465367
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures--a study of patients with non-insulin-dependent diabetes mellitus.J Clin Pharm Ther. 1993 Aug;18(4):295-9. doi: 10.1111/j.1365-2710.1993.tb00591.x. J Clin Pharm Ther. 1993. PMID: 8227238 Clinical Trial.
-
An overview of metformin in the treatment of type 2 diabetes mellitus.Am J Med. 1997 Jan;102(1):99-110. doi: 10.1016/s0002-9343(96)00353-1. Am J Med. 1997. PMID: 9209206 Review.
Cited by
-
Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.BMJ Open Diabetes Res Care. 2022 Sep;10(5):e002894. doi: 10.1136/bmjdrc-2022-002894. BMJ Open Diabetes Res Care. 2022. PMID: 36220195 Free PMC article.
-
Heterocyclic compounds as a magic bullet for diabetes mellitus: a review.RSC Adv. 2022 Aug 16;12(35):22951-22973. doi: 10.1039/d2ra02697j. eCollection 2022 Aug 10. RSC Adv. 2022. PMID: 36105949 Free PMC article. Review.
-
Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study.J Diabetes Metab Disord. 2022 Jan 29;21(1):219-228. doi: 10.1007/s40200-021-00961-6. eCollection 2022 Jun. J Diabetes Metab Disord. 2022. PMID: 35673517 Free PMC article.
-
Patient's awareness on COPD is the strongest predictor of persistence and adherence in treatment-naïve patients in real life: a prospective cohort study.BMC Pulm Med. 2021 Nov 27;21(1):388. doi: 10.1186/s12890-021-01754-6. BMC Pulm Med. 2021. PMID: 34837978 Free PMC article.
-
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.Diabetes Obes Metab. 2022 Jan;24(1):61-71. doi: 10.1111/dom.14548. Epub 2021 Sep 28. Diabetes Obes Metab. 2022. PMID: 34514692 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical